Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

被引：0
|
作者：
Qiaoyun Tan
Liyuan Dai
Yanrong Wang
Shuxia Liu
Te Liang
Rongrong Luo
Shasha Wang
Ning Lou
Haizhu Chen
Yu Zhou
Qiaofeng Zhong
Jianliang Yang
Puyuan Xing
Xingsheng Hu
Yutao Liu
Shengyu Zhou
Jiarui Yao
Di Wu
Zhishang Zhang
Le Tang
Xiaobo Yu
Xiaohong Han
Yuankai Shi
机构：
[1] Department of Medical Oncology,
[2] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,undefined
[3] Chinese Academy of Medical Sciences & Peking Union Medical College,undefined
[4] Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs,undefined
[5] State Key Laboratory of Proteomics,undefined
[6] Beijing Proteome Research Center,undefined
[7] National Center for Protein Sciences-Beijing (PHOENIX Center),undefined
[8] Beijing Institute of Lifeomics,undefined
[9] Clinical Pharmacology Research Center,undefined
[10] Peking Union Medical College Hospital,undefined
[11] State Key Laboratory of Complex Severe and Rare Diseases,undefined
[12] NMPA Key Laboratory for Clinical Research and Evaluation of Drug,undefined
[13] Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs,undefined
[14] Chinese Academy of Medical Sciences & Peking Union Medical College,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Anti-PD1/PDL1 lgG; Subclass; Anti-PD1 IgG4; Biomarker; Anti-PD1 therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1681 / 1691
页数：10
相关论文
共 50 条
  • [41] A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.
    Weidhaas, Joanne B.
    Scheffler, Aaron Wolfe
    Salzman, David
    Kalbasi, Anusha
    Wilenius, Kirk
    Rietdorf, Emily
    Heilig, Mara
    Pitka, Mattias
    Desler, Caroline
    Ruan, Dan
    Ribas, Antoni
    Drakaki, Alexandra
    Scholz, Mark C.
    Telesca, Donatello
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [42] Interchangeability of anti-PD1 antibodies in patients (pts) with metastatic NSCLC
    Kravchuk, Darya
    Fedyanin, Mikhail
    Ivan, Borovkov
    Moiseenko, Fedor Vladimirovich
    Zhukova, Lyudmila
    Pokataev, Ilya
    Rays, Anastasia
    Chubenko, Viacheslav
    Volkov, Nikita
    Ivanilov, Kirill
    Glazkova, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Hypertrophic lichenoid reactions secondary to anti-PD1 therapy
    Vu, M.
    Shackleton, M.
    Brady, B.
    Pan, Y.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 99 - 99
  • [44] Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
    Sun, Yiting
    Jiang, Liqing
    Wen, Ti
    Guo, Xiaoyu
    Shao, Xinye
    Qu, Hui
    Chen, Xi
    Song, Yujia
    Wang, Fang
    Qu, Xiujuan
    Li, Zhi
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [45] Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
    Garces, Alvaro H. Ingles
    Au, Lewis
    Mason, Robert
    Thomas, Jennifer
    Larkin, James
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 695 - 708
  • [46] Impact of anti-PD1 on TIL phenotype and function
    Creasy, Caitlin
    Haymaker, Cara
    Forget, Marie-Andree
    Singh, Gopal
    Tapia, Coya
    Painter, Jeane Marie
    Meric-Bernstam, Funda
    Bernatchez, Chantale
    Naing, Aung
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [47] Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models
    Wang, Sarah
    Sun, Kaiming
    Xiao, Yonghong
    Feng, Bin
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [49] Auranofin enhances the efficacy of anti-PD1 immunotherapy
    Zhao, Zichen
    Hu, Shichuan
    Zhang, Yan
    CANCER RESEARCH, 2024, 84 (06)
  • [50] How to build anti-PD1 agonist antibodies
    Alexandra Flemming
    Nature Reviews Immunology, 2023, 23 : 139 - 139
12345